Urolithin A,
does it really help with Improved muscle endurance and exercise performance in middle-aged and older adults?
research showsUrolithin A is rated C because selected muscle-endurance and strength measures improved in middle-aged and older adults. In a 66-person trial, both coprimary outcomes, six-minute walk distance and hand-muscle ATP production, were null. Muscle endurance improved only as a secondary endpoint at two months, and the difference disappeared at four months. An 88-person trial also missed its peak-power primary endpoint. Small samples and extensive Amazentis conflicts limit the result to C with 44 points.
ads claimMarketing can connect mitophagy activation directly to stronger muscles, longer walking, and reversal of aging. Human evidence is limited to selected measures in small four-month branded-ingredient trials, with failed key performance endpoints and no long-term independent confirmation.
Useful facts when choosing a product
- Mitopure is an Amazentis-developed branded urolithin A ingredient, and clinical trials used 500 mg or 1,000 mg daily for four months. Actual content and additional ingredients in marketed products should be checked on the label.
- Urolithin A can be produced when gut microbes metabolize pomegranate and other ellagitannins, but natural production capacity varies substantially among people. A supplement supplies a standardized compound without relying on that conversion.
- Published short trials found no clear adverse-event difference from placebo and generally good tolerability, but safety has not been established in thousands of users or over long-term use.
- Persistent muscle loss, impaired walking, breathlessness, or fatigue warrants evaluation; a supplement should not replace resistance exercise, adequate protein, or treatment of an underlying disorder.
What the research actually shows
Liu and colleagues randomized 66 adults aged 65 to 90 to 1,000 mg of urolithin A or placebo for four months. Both coprimary outcomes, six-minute walk and ATP production, were null. Endurance improved at two months as a secondary endpoint, but the difference disappeared at four months. Singh and colleagues randomized 88 untrained overweight middle-aged adults to 500 mg, 1,000 mg, or placebo for four months; peak power was null, while selected leg-strength and aerobic measures improved. Amazentis sponsored both papers.
Why this is classified as C (44)
Two randomized trials found selected endurance, strength, and aerobic improvements, but both coprimary six-minute-walk and ATP-production outcomes and a separate peak-power primary endpoint were null. Endurance was positive only at two months as a secondary endpoint and disappeared at four months. Small samples and Amazentis/Mitopure conflicts give C with 44 points.
Counterpoint. Individualized resistance and aerobic activity, adequate nutrition, and evaluation of muscle decline remain central, while urolithin A is an unconfirmed adjunct.
Rejudgment record. New verdict — Accepted selected muscle-endurance and strength signals, while reflecting null coprimary outcomes in the 66-person trial, an endurance secondary endpoint that was positive only at two months and absent at four months, a failed peak-power endpoint, small samples, and Amazentis/Mitopure concentration
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved muscle endurance and exercise performance in middle-aged and older adults | C | Two small randomized trials found selected positive measures, but key primary endpoints failed and manufacturer concentration is substantial. |
| Mitophagy and mitochondrial-marker improvement guarantees clinical benefit | ? | No direct literature establishes that protein or metabolite changes translate into long-term functional benefit experienced by patients. |
| Extension to treatment of sarcopenia or prevention of falls and disability | ? | No confirmatory trial has assessed clinical outcomes such as falls or disability in patients with sarcopenia. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Liu S et al. 2022 | Four-month randomized double-blind placebo-controlled clinical trial | 66 | Sponsored by Amazentis, with employee and board-member coauthors | Coprimary six-minute walk distance and maximal hand-muscle ATP production; secondary endurance and plasma markers | Both coprimary outcomes were null, while two-month endurance and selected plasma markers were positive. | Pivotal direct trial with failed primary outcomes |
| Singh A et al. 2022 ATLAS | Four-month randomized double-blind placebo-controlled dose trial | 88 | Sponsored by Amazentis, with multiple employee, board, and advisory authors | Peak-power primary endpoint; leg strength, VO2, six-minute walk, and mitochondrial markers | Peak power was not significant, while selected leg-strength, aerobic, and surrogate measures improved. | Direct branded-ingredient trial with selected positive findings |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Urolithin A x improved muscle endurance and exercise performance in middle-aged and older adults — Evidence Grade C·44. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/urolithin-a-mitopure-muscle-endurance-exercise-performance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.